We can’t show the full text here under this license. Use the link below to read it at the source.
Review of glucagon‐like peptide‐1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects
Glucagon-like peptide-1 drugs for treating type 2 diabetes in people with chronic kidney disease and their effects on the kidneys
AI simplified
Abstract
GLP-1 receptor agonists (GLP-1RAs) may effectively reduce hyperglycemia in patients with mild or moderately impaired kidney function.
- Glycemic control with GLP-1RAs was not markedly less effective in patients with mild or moderate renal impairment compared to those with normal kidney function.
- GLP-1RAs are associated with improvements in cardiorenal risk factors, such as systolic blood pressure and body weight.
- Several large cardiovascular outcome studies indicated reduced risks of composite renal outcomes, primarily due to a decrease in macroalbuminuria.
- Limited studies suggest potential renoprotective effects of GLP-1RAs that warrant further investigation.
AI simplified
Key numbers
−1.4%
HbA1c Reduction with Exenatide
Reduction in HbA1c for eGFR 30-59 mL/min/1.73 m
−39.6 mg/g
Albuminuria Reduction with GLP-1RAs
Mean decrease in albuminuria in GLP-1RA-treated patients
5.8%
Composite Renal Outcome Reduction
Incidence of composite renal outcome with exenatide vs placebo